)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
EMVision Medical Devices
EMVision Medical Devices (EMV) investor relations material
EMVision Medical Devices Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary25 Oct, 2026
Executive summary
Pivotal Trial recruitment exceeded 230 patients by early October; majority are in the 300-participant primary analysis cohort supporting planned FDA De Novo submission for emu™.
Cash reserves were $18.1m at quarter end, with $3.7m remaining under current grant programs.
Financial highlights
Quarter-end cash and cash equivalents were $18.091m, versus $17.104m at 30 June 2026.
Net operating cash inflow was $1.008m, including $4.296m R&D tax incentive, $0.650m Industry Growth Program and $0.307m CRC-P receipts.
Quarter cash payments included R&D $1.004m, staff $2.372m and administration/corporate costs $0.833m.
The FY2026 R&D tax incentive rebate was $4.3m, versus $3.8m for FY2025.
Outlook and guidance
Primary analysis cohort enrolment target is ~300 participants; completion is targeted for early CY27, with data lock and independent analysis targeted for mid-CY27.
FDA De Novo submission is targeted for H2 CY27 following trial readout; milestone timing is indicative and subject to enrolment rates and regulatory feedback.
Production-equivalent First Responder units are targeted for H1 CY27; standard road ambulance study commencement is targeted for H2 CY27.
A successful Pivotal Trial result could support emu™ De Novo submission, the First Responder 510(k) pathway and transition toward commercialisation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from EMVision Medical Devices
- Promising stroke classification performance with expanding multicenter ED evaluation.EMV
Investor presentation - Pivotal trials advance for portable neurodiagnostics, with strong financials and US launch focus.EMVH2 2026
- Cash reserves rose to $18.4 million as pivotal trials and pre-hospital studies advanced.EMVQ3 2026 TU
- Revenue up 63% to $11.56M, net loss down 29%, $15.28M investment secured.EMVH2 2024
- Net loss widened to $9.81M on lower revenue as clinical and commercial activities accelerated.EMVH2 2025
- Portable brain scanner targets faster stroke care with pivotal trials and global partnerships.EMVNWR Virtual Healthcare Conference
- Portable brain scanners with strong clinical data target U.S. launch and global expansion by 2027.EMVLife Sciences Virtual Investor Forum
- Loss widened but strong cash and grant pipeline support pivotal trials and US-focused growth.EMVH1 2026
- $17.5M cash, robust clinical trial progress, and nearly 7 quarters of funding runway.EMVQ2 2026 TU
Next EMVision Medical Devices earnings date
H1 202721 Feb, 2027
EMVision Medical Devices
Next EMVision Medical Devices earnings date
H1 202721 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
EMVision Medical Devices Ltd is a medical technology company focused on the development of non-invasive imaging solutions for the diagnosis and monitoring of neurological disorders. The company’s primary innovation is its portable brain scanner, designed to use electromagnetic microwave imaging technology to rapidly detect and monitor conditions such as strokes. EMVision aims to provide healthcare professionals with accurate, bedside imaging tools that can improve the speed and effectiveness of patient care, particularly in emergency settings. EMVision Medical Devices Ltd is headquartered in Sydney, Australia, and its shares are listed on the ASX.